Skip Navigation


Carcinogenesis Advance Access originally published online on June 12, 2008
Carcinogenesis 2008 29(7):1351-1359; doi:10.1093/carcin/bgn133
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/7/1351    most recent
bgn133v2
bgn133v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gylling, A.H.S.
Right arrow Articles by Peltomäki, P.T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gylling, A.H.S.
Right arrow Articles by Peltomäki, P.T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors

A.H.S. Gylling1, T.T. Nieminen1, W.M. Abdel-Rahman1,2, K. Nuorva3, M. Juhola3, E.I. Joensuu1, H.J. Järvinen4, J.-P. Mecklin5, M. Aarnio5 and P.T. Peltomäki1,*

1 Department of Medical Genetics, University of Helsinki, Helsinki, Finland
2 College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
3 Department of Pathology, Jyväskylä Central Hospital, Jyväskylä, Finland
4 Second Department of Surgery, Helsinki University Hospital, Helsinki, Finland
5 Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland

* To whom correspondence should be addressed. Department of Medical Genetics, Biomedicum Helsinki, PO. Box 63 (Haartmaninkatu 8), University of Helsinki, Finland, FIN-00014. Tel: +358 9 19125092; Fax: +358 9 19125105; Email: paivi.peltomaki{at}helsinki.fi

Hereditary non-polyposis colorectal carcinoma (Lynch syndrome) is among the most common hereditary cancers in man and a model of cancers arising through deficient DNA mismatch repair (MMR). Lynch syndrome patients are predisposed to different cancers in a non-random fashion, the basis of which is poorly understood. We addressed this issue by determining the molecular profiles for different tumors from a nationwide cohort of Lynch syndrome families (~150 tumors in total). We focused on some less prevalent cancers, affecting the brain (n = 7) and urinary tract (five bladder and five ureter uroepithelial cancers and four kidney adenocarcinomas), and compared their molecular characteristics to those of the most common cancers, colorectal, gastric and endometrial adenocarcinomas, from the same families. Despite origin from verified MMR gene mutation carriers, the frequency of high-level microsatellite instability in tumors varied between high (100–96% for ureter, stomach and colon), intermediate (63–60% for endometrium and bladder) and low (25–0% for kidney and brain). In contrast to gastrointestinal and endometrial carcinomas, active (nuclear) β-catenin was rare and KRAS mutations were absent in brain and urological tumors. Compared with other tumors, frequent stabilization of p53 protein characterized urinary tract cancers. Promoter methylation of tumor suppressor genes discriminated the tumors in an organ-specific manner. Our findings suggest that different Lynch syndrome tumors develop along different routes. Uroepithelial cancers of the ureter (and bladder to lesser extent) share many characteristics of MMR deficiency-driven tumorigenesis, whereas brain tumors and kidney adenocarcinomas follow separate pathways.

Abbreviations: ACVR2, activin A type II receptor; APC, adenomatous polyposis coli; LOH, loss of heterozygosity; MLPA, multiplex ligation-dependent probe amplification; MMR, mismatch repair; MRE11A, meiotic recombination 11 homolog; MS, methylation specific; MSI, microsatellite instability; MSS, microsatellite stable; PCR, polymerase chain reaction; PTEN, phosphatase and tensin homolog

Received January 3, 2008; revised May 21, 2008; accepted May 25, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
T. T. Nieminen, A. Gylling, W. M. Abdel-Rahman, K. Nuorva, M. Aarnio, L. Renkonen-Sinisalo, H. J. Jarvinen, J.-P. Mecklin, R. Butzow, and P. Peltomaki
Molecular Analysis of Endometrial Tumorigenesis: Importance of Complex Hyperplasia Regardless of Atypia
Clin. Cancer Res., September 15, 2009; 15(18): 5772 - 5783.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.